EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Abstract
Receptor tyrosine kinase genes were sequenced in non–small cell lung cancer (NSCLC) and matched normal tissue. Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15of 58 unselected tumors from Japan and 1 of 61 from the United States. Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan. EGFR mutations were found in additional lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines. These results suggest that EGFR mutations may predict sensitivity to gefitinib.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 04, 2004
- Source ID
- 10.1126/science.1099314
Entities
People
- Bruce E. Johnson
- Frederic J. Kaye
- Heidi Greulich
- Hidefumi Sasaki
- J. Guillermo Paez
- Jeffrey C. Lee
- Katsuhiko Naoki
- Matthew Meyerson
- Michael J. Eck
- Neal Lindeman
- Pasi A. Jänne
- Paula Herman
- Sean Tracy
- Stacey Gabriel
- Titus J. Boggon
- William R Sellers
- Yoshitaka Fujii
Organizations
- Dana–Farber Cancer Institute
- Harvard Medical School
- National Cancer Institute